VivoSeq
Other

Hyperbilirubinemia

18

Pipeline Programs↗

4

Active Trials↗

10

Companies Involved↗

Hyperbilirubinemia is an emerging landscape with 18 programs across 10 companies. The most active players are Bristol-Myers Squibb, InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company, Johnson & Johnson. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

80/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1I

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2Sanofi logo

Sanofi

1 program

ApprovedDaewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

ApprovedPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Recruiting4 · 24%
Unknown status3 · 18%
Terminated2 · 12%

Clinical Trials

Trial Activity

17 trials

COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY
Recruiting·QQuaid-e-Azam Medical College·Phase 2·NCT07102836·110 enrolled
The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia
Recruiting·TTishreen University Hospital·N/A·NCT07110987·70 enrolled
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06922669·232 enrolled
Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia
Recruiting·—·Phase 4·NCT06517862·80 enrolled
Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00004382·80 enrolled
Effects of Probiotics on Neonatal Hyperbilirubinemia
Completed·KKaradeniz Technical University·N/A·NCT02807246·150 enrolled
Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia
Completed·NNational Liver Institute, Egypt·Phase 3·NCT06227624·192 enrolled
Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
Completed·OOswaldo Cruz Foundation·Phase 4·NCT00288600·92 enrolled
Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants
Completed·MMansoura University·N/A·NCT04418180
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00004381
Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial
Completed·—·Phase 1/2·NCT00692224·294 enrolled
The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia
Completed·RRadboud University Medical Center·N/A·NCT00916448·30 enrolled
A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Terminated·IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company·Phase 2·NCT00850993·58 enrolled
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT02267707·1 enrolled
Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial
Unknown status·SShaheed Zulfiqar Ali Bhutto Medical University·N/A·NCT04868019·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)